Greenwich LifeSciences shares are rising, with the company's breast cancer vaccine trial data reportedly a driving factor. The stock's pre-market increase is also being discussed alongside other market developments, including investor reactions to middle east news and a us jobs report. The specific reasons for the rise are still being parsed by investors and analysts.